Beyond Signal Detection: Sequential Target Trial Emulations to Confirm Previously Detected Adverse Drug Event Signals for Atorvastatin in Older Medicare Beneficiaries

Background and objective

High dimensional, hypothesis free signal detection in claims data can identify adverse drug events (ADEs), yet these exploratory signals remain vulnerable to false positives and residual confounding. Rigorous internal confirmation using causal inference methods is therefore a critical intermediate step in a staged pharmacovigilance paradigm before external validation. We aimed to confirm or refute previously detected ADE signals associated with atorvastatin initiation among older adults after myocardial or cerebral infarction.

Methods

Internal confirmatory sequential target trial emulations were conducted using Medicare fee for service claims (2017–2019). Eligible participants were statin naive beneficiaries aged ≥ 65 years hospitalized for myocardial or cerebral infarction. Up to 14 nested daily trials were constructed beginning on the discharge date. Pragmatic treatment strategies compared atorvastatin initiation with initiation of a different new outpatient medication. Per protocol effects were estimated using inverse probability weighted Fine-Gray models treating death as a competing risk. Previously detected ADE signals and clinically coherent alternatives within the same outcome families were evaluated. Confirmation required survival of within outcome false discovery rate control and persistence under probabilistic quantitative bias analysis (dual criteria). Absolute risks and numbers needed to harm (NNH) were reported. A prespecified sensitivity analysis restricted inference to the first two trials with optimal covariate balance; a post hoc analysis examined effect modification by concomitant high risk antithrombotic therapy.

Results

Of 70,130 eligible patients, 39,948 initiated atorvastatin (81% high intensity) and 19,182 initiated a different new medication. After weighting, baseline characteristics were closely balanced. Associations meeting dual confirmatory criteria formed a gradient of support. The strongest findings were early (days 1 to 30) acute hemorrhagic cerebrovascular disease (sHR 2.20, 95% CI 1.35–3.58; NNH 351) and acute hepatic failure (sHR 1.72, 1.16–2.55; NNH 468), both robust to high risk antithrombotic therapy and to the restricted trial set with optimal covariate balance. Intermediate support was observed for biliary tract disease (women; sHR 1.45, 1.14–1.85; NNH 102) and musculoskeletal injuries (men; sHR 1.66, 1.24–2.21; NNH 71). Tentative evidence was observed for cardiac valve disorders (attenuated in the absence of high risk antithrombotic therapy) and sensory symptoms (non-White patients). Prediabetes and posthemorrhagic anemia were not confirmed.

Conclusions

Several previously detected ADE associations with atorvastatin initiation met dual confirmatory criteria and formed a gradient of confirmatory support. Strongest evidence supported early hemorrhagic cerebrovascular disease, hepatic dysfunction, and musculoskeletal injuries. Absolute excess risks were modest yet clinically relevant to a high risk post-infarction population (NNH 71-468) and must be interpreted alongside the established benefits of high intensity statin therapy (number needed to treat to prevent one event (NNT) 28–93). These findings support a two stage active pharmacovigilance paradigm (signal detection followed by rigorous confirmation) and justify heightened clinical vigilance for the confirmed events, while underscoring the need for external validation in independent populations and data sources.

KEY POINTS

Question: Can previously detected signals of adverse drug events associated with atorvastatin initiation in older adults be confirmed under more rigorous dual confirmatory criteria?

Findings: In this internal confirmatory Medicare claims study using sequential target trial emulation, associations meeting dual confirmatory criteria formed a gradient of support. The strongest findings were early acute hemorrhagic cerebrovascular disease (sHR 2.20) and acute hepatic failure (sHR 1.72), both robust to high risk antithrombotic therapy and to the optimally balanced early trials. Intermediate support was observed for biliary tract disease and musculoskeletal injuries. Weaker evidence was observed for cardiac valve disorders (attenuated in the absence of high risk antithrombotic therapy) and sensory symptoms. Prediabetes and posthemorrhagic anemia were not confirmed.

Meaning: Although atorvastatin remains foundational for secondary cardiovascular prevention (NNT 28–93 to prevent one event), these findings support heightened clinical vigilance for early hemorrhagic, hepatic, and musculoskeletal events in older adults after myocardial or cerebral infarction, while underscoring the need for external validation.

PLAIN LANGUAGE SUMMARY

Older adults who start atorvastatin after a heart attack or stroke may face a higher risk of certain serious side effects, according to this large study of Medicare insurance records.

Researchers previously identified possible safety signals for atorvastatin using advanced methods that mimic clinical trials with real world data. This follow up study carefully reexamined those signals with stricter eligibility rules, more precise outcome definitions, and statistical techniques designed to reduce false findings.

The analysis confirmed a range of associations that varied in strength. The strongest evidence pointed to higher rates of bleeding in the brain (especially in the first 30 days) and acute liver failure. Intermediate evidence supported bile duct problems and muscle strains or joint injuries. Weaker evidence was found for certain heart valve problems and for dizziness or sensory symptoms. Some earlier possible signals, such as prediabetes, were not confirmed.

Although atorvastatin remains an important treatment to prevent future heart attacks and strokes, these findings suggest that older adults starting the drug may benefit from close monitoring for early bleeding in the brain, liver problems, and muscle or joint injuries, and that suspicion for these should be heightened when suggestive symptoms present following atorvastatin initiation. Patients and clinicians should discuss these potential risks, remain alert to early warning signs, and recognize that further studies in other populations are still needed to confirm the results.